Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.
Their study appears in a recent issue of Cancer Research, published by the American Association for Cancer Research.
"Despite good initial response to first-line treatment with chemotherapy and monoclonal antibodies, almost all patients with MCL will eventually relapse," said Eduardo M. Sotomayor, M.D., a senior member at Moffitt and the Susan and John Sykes Endowed Chair for Hematologic Malignancies. "MCL has one of the worst prognoses among all B-cell non-Hodgkin lymphomas."
Moffitt researchers and colleagues have exploited evidence that suggests the manipulation of the patient's own immune system might prove a good therapeutic strategy for patients with therapy-resistant MCL.
In a study using mouse models of MCL, the researchers hypothesized that targeting and inhibiting STAT3 a "negative regulator" of inflammatory responses in a variety of immune cells might "unleash an effective anti-lymphoma immune response."
According to Sotomayor, much of their work is in seeking new immunotherapeutic strategies capable of breaking tolerance to tumor antigens that is finding ways to defeat lymphoma cells' ability to resist treatment.
In this study, the researchers found that the inhibition of STAT3 in malignant B-cells, either by genetic manipulation or by using drugs (CPA-7 provided by Said M. Sebti, Ph.D., chair of the Drug Discovery Program at Moffitt and co-author of this study), render these cells "more visible" to specific immune cells (T-cells), which in turn can eradicate mantle cell lymphoma in murine
|Contact: Kim Polacek|
H. Lee Moffitt Cancer Center & Research Institute